JP7508447B2 - 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸 - Google Patents

血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸 Download PDF

Info

Publication number
JP7508447B2
JP7508447B2 JP2021515298A JP2021515298A JP7508447B2 JP 7508447 B2 JP7508447 B2 JP 7508447B2 JP 2021515298 A JP2021515298 A JP 2021515298A JP 2021515298 A JP2021515298 A JP 2021515298A JP 7508447 B2 JP7508447 B2 JP 7508447B2
Authority
JP
Japan
Prior art keywords
compound
formula
subject
pharmaceutical composition
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515298A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019224602A5 (https=
JP2021526552A5 (https=
JP2021526552A (ja
Inventor
アラン フレイザー，ディヴィッド
スクジェレット，トーレ
シュパン，デトレフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
Pronova Biocare AS
Pronova Biopharma Norge AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biocare AS, Pronova Biopharma Norge AS filed Critical Pronova Biocare AS
Publication of JP2021526552A publication Critical patent/JP2021526552A/ja
Publication of JPWO2019224602A5 publication Critical patent/JPWO2019224602A5/ja
Publication of JP2021526552A5 publication Critical patent/JP2021526552A5/ja
Application granted granted Critical
Publication of JP7508447B2 publication Critical patent/JP7508447B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021515298A 2018-05-23 2019-05-22 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸 Active JP7508447B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180714 2018-05-23
NO20180714 2018-05-23
PCT/IB2019/000655 WO2019224602A2 (en) 2018-05-23 2019-05-22 Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease

Publications (4)

Publication Number Publication Date
JP2021526552A JP2021526552A (ja) 2021-10-07
JPWO2019224602A5 JPWO2019224602A5 (https=) 2022-05-30
JP2021526552A5 JP2021526552A5 (https=) 2022-05-30
JP7508447B2 true JP7508447B2 (ja) 2024-07-01

Family

ID=67688797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515298A Active JP7508447B2 (ja) 2018-05-23 2019-05-22 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸

Country Status (8)

Country Link
US (2) US20210290576A1 (https=)
EP (1) EP3796901A2 (https=)
JP (1) JP7508447B2 (https=)
KR (2) KR20250150676A (https=)
CN (1) CN112351775A (https=)
AU (1) AU2019274203B2 (https=)
CA (1) CA3101041A1 (https=)
WO (1) WO2019224602A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102760537B1 (ko) 2022-01-20 2025-02-03 한국과학기술연구원 삼원계 광활성층 조성물 및 이를 포함하는 유기태양전지

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528350A (ja) 2008-07-15 2011-11-17 プロノヴァ バイオファーマ ノルゲ アーエス 補助食品としてまたは薬剤として使用するための新規硫黄含有脂質
JP2012526094A (ja) 2009-05-08 2012-10-25 プロノヴァ・バイオファーマ・ノルゲ・アーエス 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
JP2013525471A (ja) 2010-05-05 2013-06-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620272B2 (ja) 2007-11-09 2014-11-05 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ ＮｏｒｇｅＡＳ 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
JP2013517322A (ja) 2010-01-20 2013-05-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス サリチレート脂肪酸誘導体
PL2961727T3 (pl) 2013-02-28 2017-06-30 Pronova Biopharma Norge As Sposób wytwarzania kwasu 2-((5Z,8Z, 11Z,14Z,17Z)-ejkoza-5,8,11,14,17-pentaenyloksy)butanowego
US20180110747A1 (en) 2015-04-01 2018-04-26 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
BR112017023164A2 (en) * 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528350A (ja) 2008-07-15 2011-11-17 プロノヴァ バイオファーマ ノルゲ アーエス 補助食品としてまたは薬剤として使用するための新規硫黄含有脂質
JP2012526094A (ja) 2009-05-08 2012-10-25 プロノヴァ・バイオファーマ・ノルゲ・アーエス 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
JP2013525471A (ja) 2010-05-05 2013-06-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Controlled Release，2008年，132，pp.99-104

Also Published As

Publication number Publication date
KR20210015883A (ko) 2021-02-10
WO2019224602A3 (en) 2020-03-05
CN112351775A (zh) 2021-02-09
AU2019274203B2 (en) 2025-01-02
AU2019274203A1 (en) 2021-01-07
EP3796901A2 (en) 2021-03-31
US20210290576A1 (en) 2021-09-23
US20260000632A1 (en) 2026-01-01
WO2019224602A2 (en) 2019-11-28
KR20250150676A (ko) 2025-10-20
CA3101041A1 (en) 2019-11-28
JP2021526552A (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7479278B2 (ja) Ａｃｃ阻害剤を含む併用療法
CN105120872B (zh) 包含15-hepe的组合物以及其使用方法
JP7548669B2 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN105189438A (zh) 用于治疗纤维化的经取代的芳族化合物及相关方法
JP2021183640A (ja) 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
JP7368354B2 (ja) 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2019142925A (ja) 糖尿病の治療用組成物および方法
US20260000632A1 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
US20140128402A1 (en) Pharmaceutical combination
EP3548026A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
JP2018197273A (ja) 脂質異常症治療剤
JP6761347B2 (ja) 脂質異常症治療剤
KR20230128307A (ko) 비알코올성 지방간염의 치료를 위한 산소-함유 구조적으로개선된 지방산을 포함하는 병용요법
WO2014030624A1 (ja) スチルベン誘導体を有効成分として含有する筋緊張性ジストロフィー治療剤
TW202541795A (zh) 用於預防及/或治療肝疾病之組合療法
CN119730845A (zh) 用于改善视网膜/认知功能和动脉粥样硬化的极长链多不饱和脂肪酸（vlcpufa）
HK1200351B (en) Compositions comprising 15-hepe and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240619

R150 Certificate of patent or registration of utility model

Ref document number: 7508447

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150